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We have determined the primary structure of the u,(IV)-chain of human type IV collagen by nucleotide 
sequencing of overlapping cDNA clones that were isolated from a human placental cDNA library. The pres- 
ent data provide the sequence of 295 amino acids not previously determined. Altogether, the a,(IV)-chain 
contains 1642 amino acids and has a molecular mass of 157625 Da. There are 1413 residues in the colla- 
genous domain and 229 amino acids in the carboxy-terminal globular domain. The human a,(IV)-chain 
contains a total of 21 interruptions in the collagenous Gly-X-Y repeat sequence. These interruptions vary 
in length between two and eleven residues. The a,(IV)-chain contains four cysteine residues in the triple- 
helical domain, four cysteines in the 15-residue long noncollagenous sequence at the amino-terminus and 
12 cysteines in the carboxy-terminal NC-domain. 
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1. INTRODUCTION 
Type IV collagen is the major structural compo- 
nent of basement membranes [ 11. The molecule 
contains two distinct polypeptide chains, BUD 
and cyz(IV), with molecular masses of 185 and 
170 kDa, respectively [2]. Three a-chains form a 
heterotrimer that apparently contains two (YI(IV)- 
and one az(IV)-chain [3] but a homotrimer of 
aI(chains has also been described [4]. The 
molecule contains an about 350 nm long triple- 
helical collagenous domain with a large globule at 
the carboxy-terminal end [ 11. In contradiction with 
the fibrillar collagens of types I, II, III and V [5], 
type IV collagen forms a network structure. 
Correspondence address: K. Tryggvason, Biocenter and 
Department of Biochemistry, University of Oulu, 
SF-90570 Oulu, Finland 
The nucleotide sequence presented here has been submit- 
ted to the EMBL/GenBank database under accession 
number YOO706 
Another significant difference from fibrillar col- 
lagens is that the triple helix of the type IV collagen 
molecule has imperfections in the collagenous Gly- 
X-Y- repeat sequence [ 11. Interrupted triple helices 
are also found in collagen types VI, VII, VIII, IX 
and X that do not form fibrils [6-lo]. 
A part of the amino acid sequence of the a,(IV)- 
chain from several species has been determined by 
amino acid and nucleotide sequencing. The amino 
acid sequence of a 914-residue long pepsin frag- 
ment representing about two-thirds of the carboxy- 
terminal end of the collagenous domain [ 1 l] and 
the sequence of a 216-residue long fragment from 
the amino-terminus of the human aI(chain has 
been determined by protein sequencing [ 121. We 
and others [ 13,141 have determined the complete 
primary structure of the carboxy-terminal globular 
domain of the human cul(IV)-chain by analysis of 
cDNA clones. For mouse, the structure of the 
globular domain and 511 residues from the 
carboxy-terminal end of the triple-helical region 
has been determined by a combination of protein 
and cDNA sequencing [15-171. Recently, the 
188 
Published by Elsevier Science Publishers B. V. (Biomedical Division) 
00145793/87/$3.50 0 1987 Federation of European Biochemical Societies 
Volume 225, number 1,2 FEBS LETTERS December 1987 
primary structure for the carboxy-terminal 
globular domain and a part of the collagenous 
region of the az(IV)-chain was deduced from clon- 
ed cDNAs for both human [18,19] and mouse 
[20-231 type IV collagen. 
In the present study we describe the primary 
structure of the complete human cur(IV)-chain 
based on amino acid sequences derived from 
cDNA clones. 
2. MATERIALS AND METHODS 
A human placental cDNA library in the hgtll 
vector (Clontech, Palo Alto, CA) was screened 
with nick-translated probes according to standard 
techniques [24]. The initial probe was a 500 bp 
long PstI-BumHI fragment from the 5 ‘-end of the 
cDNA clone HT-21 [13] that contains sequences 
for the carboxy-terminal end of human (wi(IV)- 
chain. Most of the 5 ‘-fragments from isolated 
clones were used as probes in rescreening of the 
same library. 
Nucleotide sequencing was carried out using 
Ml3 cloning [25] and the dideoxynucleotide chain 
termination method [26] with the ‘Sequenase’ en- 
zyme (United States Biologicals, Cleveland, OH). 
In most reactions dITP was used instead of dGTP 
which enabled reading through the compression 
areas common for collagen coding cDNAs. 
Primers used for the sequencing were either the 
‘universal primer’ or specific 15-mer oligonucle- 
otide primers synthesized in a DNA synthesizer 
(Applied Biosystems). 
3. RESULTS AND DISCUSSION 
3.1. Isolation and characterization of cDNA 
clones 
Screening of the human placental cDNA library 
with the 5’-fragment from the ai(coding 
cDNA clone HT-21 resulted in the isolation of 
several clones. Two clones, HP-2 and HP-3, con- 
taining inserts of 3.5 kb and 3.0 kb, respectively, 
were further characterized. The 5 ’ -EcoRI frag- 
ment of HP-2 was then used as a probe for the 
isolation of clone HP-l, and to isolate the HP-11 
cDNA clone. Partial restriction map of the clones 
is presented in fig.1. Three clones, HP-11, HP-2 
and HP-3, cover the entire coding sequence for the 
human cut(W)-chain except for the signal peptide 
and the first 18 amino acids at the amino-terminus. 
3.2. Nucleotide sequence and primary structure 
EcoRI or BamHI restriction fragments of cDNA 
clones were cloned into Ml3 vector and sequenced 
first with the universal primer and then with 
specific synthetic primers to obtain overlapping se- 
quences. Coding sequences for regions of the 
ai(chain not previously determined by amino 
acid sequencing were sequenced from both 
strands. The nucleotide sequence of the cDNA 
clones that reached 5 ’ from the previously 
reported HT-21 [13] and the deduced amino acid 
sequence is shown in fig.2. There are 5 differences 
between the sequence determined here and those 
determined previously by amino acid sequencing 
[ 11,121, assuming that amino acids marked with X 
are (hydroxy)lysines. These differences are (i) 
asparagine instead of aspartic acid at position 692, 
(ii) aspartic acid instead of tyrosine at position 8 10, 
(iii) lysine instead of proline at position 815, (iv) 
serine instead of hydroxylysine at position 887 and 
(v) lysine instead of proline at position 983. 
The data provided the sequence of 295 amino 
acids not previously determined. The new sequence 
completed the structure of the whole chain. Ac- 
cordingly, the results established that the (Y,(W)- 
chain contains 1642 amino acids and has a 
molecular mass of 157625 Da. The collagenous 
domain has 1413 residues and the carboxy- 
terminal globular domain has 229 amino acids 
[ 131. In vitro translation of the mRNA specific to 
mouse type IV collagen cDNA resulted in the syn- 
thesis of a polypeptide with an apparent molecular 
mass of 165 kDa [27]. The apparent 185 kDa size 
[2] of the ai(chain on SDS-PAGE can be at- 
tributed to the presence of carbohydrates [l]. 
The noncollagenous carboxy-terminal domain 
has usually been referred to as the NC-l domain, 
because early results suggested that there would be 
a 10 kDa NC-2 domain within the triple helix [l]. 
However, the present data demonstrate that such a 
sizable NC-2 domain is not present in the cui(IV)- 
chain and therefore, we refer to the carboxy- 
terminal globule as the NC (noncollagenous) 
domain. 
The new sequence described here contains 5 im- 
perfections in the Gly-X-Y repeat sequence and, 
therefore, the human ai(chain contains a total 
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Fig. 1. Overlapping cDNA clones coding for the al-chain of human type IV collagen. HT-21 has been described in [13]. 
Its 5’-fragment was used as a probe to isolate clones HP-2 and HP-3. EcoRI (E) and BamHI (B) restriction sites are 
indicated. TAA is the site of translation termination and AAA indicates the poly(A) tail. 
of 21 interruptions (fig.3). These interruptions 
vary in length between 2 and 11 residues (table 1). 
As can be seen in fig.3, the interruptions are scat- 
tered throughout the chain, although most of them 
are located towards the amino-terminus. In addi- 
tion to the interrupted Gly-X-Y sequence, the 
ai(chain has a 229-residue long non- 
collagenous sequence at the carboxy-terminus and 
a short 15-residue long noncollagenous sequence at 
the amino-terminus [ 121. 
There are several reports about type IV collagen 
promoting cell attachment (see [ 11) and, therefore, 
one might expect the molecule to contain amino 
acid sequences recognized by membrane receptors 
for matrix components. An Arg-Gly-Asp sequence 
has been shown to play an important role in the 
adhesion of cells to components of the interstitial 
connective tissue such as fibronectin and type I col- 
lagen but also to vitronectin [28,29]. There are 
three such sequences in the human Lui(IV)-chain 
(fig.2) and one of them, Arg-Gly-Asp-Thr-Gly, is 
identical with a sequence present in the human 
@z-chain of type I collagen that supports cell at- 
tachment [29]. It is possible that these tripeptide 
sequences within the ai(chain are involved in 
mediating cell-matrix interactions. 
The type IV collagen a-chains are linked to each 
other within the triple-helical domain by disulfide 
bonds whereas the cysteine residues in the NC do- 
main only participate in intrachain bonds [30]. The 
results of this study demonstrate that, in addition 
to the 12 cysteine residues in the NC domain, there 
are four cysteine residues in the noncollagenous se- 
quence at the amino-terminus and four within the 
triple-helical domain. One of the cysteine residues 
in the collagenous domain is in a Gly-X-Y se- 
quence at location 98 (fig.2). There is one cysteine 
in interruption number 8 and two cysteines in in- 
Fig.2. Complete amino acid sequence of the ai(chain of human type IV collagen. First line: nucleotide sequence 
from the 5’-end of overlapping cDNA clones characterized in this study to the 5’-end of the previously reported 
sequence of the HT-21 cDNA [13] (fig.1). Second line: amino acid sequence deduced from the nucleotide sequence. The 
first 18 amino acids have been determined by amino acid sequencing [ 121, and amino acid residues number 1230-1642 
are deduced from the nucleotide sequence of the cDNA clone HT-21 [13]. The numbering of nucleotide sequence starts 
at the first nucleotide in the cDNA clone HP-l 1 and the numbering of the amino acid sequence at the first amino acid 
of the published sequence [12]. The new 295-residue long sequence is located between the arrows and the junction of 
the collagenous and NC-domain is marked by a vertical bar. The cysteine residues are encircled and the imperfections 
in the Gly-X-Y repeat sequence of the collagenous domain are boxed. RGD sequences are indicated by shaded boxes. 
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1 GGRCRRtlAGGGTGRRRGRGGCCTCCCGGGGlllKRA 36 
1 KGG@RGSG@GK@D@HGUKGQK GERGLPGLO 30 
37 126 
31 60 
127 216 
61 90 
217 306 
91 120 
307 GGRCCRCCRGGCTTRCCAGGG~TG~~GGGTG~TCCRttTtGCCCGGG~lGCTGTTG~~~GGTG~~~G~GGRTTT 396 
121 GPPGLPGflKGOPGElLGHUPGnLLKtERGF 150 
397 CCCGGRRTCCCRGGGRCTCCRGGCCeRCCRGGReTtCCAtGGCTTC~~GGTCCTGTTGGGCCTCCflGG~TTT~CCGG~CCRCC~GGTCCC 162 
151 PGIPGTPGPPGLPGLQGPUGPPGFTGPPGP le.0 
467 RGGACCAARRGGTGRCRAGGGTGRCCRAGGGGTCRGT 576 
161 210 
577 GGGCCTCCRGGRGTRCCAGGRCRRtCTCRRGTTCAAGRARGGG~G~fln~GGGCC~~~flnGGTG~~CCTGG~ 666 
211 GPPGUP,GQfllQUQEKGDFRTK1GEKGQ KGE PG 240 
667 TTTCRGGGGATGCC 756 
241 270 
757 616 
271 300 
617 RGGACCTTTGGGAGAAAAAGGflG~G~GGGGCTRCCeTttA~CTCCGGGGCC~~GRGG~GRG 936 
301 GPLGEKGERGVPGTPGPRGE 330 
937 TGGGCRGGCTGGTGCCCCTGGCTTCCCT 1026 
331 360 
1027 AGGACCAAGTGGRRGRGRTGGGCTCCCGGGTCCTCCTGGT III6 
361 390 
1117 TCCCCTGGGCCCCCTGGGCAGCCTGGCTACRe CGGACCTCCAGGTGACCRGGGTCCTGGARTT 1206 
391 SPGPPGQPGVT GPPGDQGPPGI 120 
1207 CCRGGGCAGCCAGGRTTTRTAOOCOAAATTOOROAORRAOTC~nn~nGG~GnGnGTT 
421 
[jCCTCRT~jTGRTATRQjCGGRTATCGGGGG 1:;; 
PGQPGFlGElGEKGQKGESCLlCDlOGVflG 
1297 1366 
(51 460 
1337 GTTGCRGGAGTGCCAGGCCCTCRAttTRCRCCAttGCTtRT~GGCCnGCC~GG~GCC~~GGGGGnGCCTGGTGRGTTTT~TTTCGnCTT~ 1176 
461 URGUPGPQGTPGLIGQPGAKGEPG EFIVFDL 
cl 
510 
1177 AGGTGRCAARGGAGRCCCRGGCTTTCC~GG~C~GCCCGGC~TGCC~GGG~GRGCGGGTTCTCCTGG~~G~GRTGGCC~TCCG 1566 
511 510 
1567 GGTCTTCCTGGCCCCARGGGCTCGCCGGGTTCTGTnGGRTTG~nnGGnG~GCGTGGCCCCCCTGGnGG~GTTGGfllTCCC~GGC~G~.~~:~ 1656 
511 G L P G P K G S P G S U G L K G E R G P P G G U G F P G S;;,'Y 570 
1657 1746 
571 600 
1717 1636 
601 630 
1637 GGCTTCCCRGGTCCCCAAGGRtACCtAttCTTTCCCOORACCCC~GGn~GGCC~GGCCTGCC~GGflG~GflflGGGCGCTGTGGGCC~GCC~ 1926 
631 GFPGPQGORGFPGTPGRPGLPGEKGRUGQP 660 
1927 2016 
661 690 
2017 TTTARTGGCTTRCCTGGGRRCCCAOOTliTOCRCOOCCROCCT TGGTCTRCCGGGRCTCAWlGGTTTGCCRGGTCTT 2106 
691 
fY FNGLPGNPGUQGQKGEPGUGLPGLKGLPGL 720 
2107 CCCGGCATTCCTGGCRCRCCCGGGGnG~RGGGGnGC~TTGGGGTnCCnGGCGTTCCTGGnG~~CnTGG~GCG~TCGGflCCCCCTGGGCTT 2196 
721 PGIPGTPGEKGSIGUPGUPGEHGRIGPPGL 750 
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751 
CRGGGGRTCAGRGGTGRRCCGGG~CCTCCTGGRTTGCCRtGCTCCGlGGGGTCTCC~GG~GTTCC~ sil RcATRGGCCCCCCTGGRGCTRGG 
QGIRGEPGPPGLPGSUGSPGUPGIGPPGRR 
2267 GGTCCCCCTGGRGGACRGGGRCCRCCOOGDTTGTCRGGTTGTCRGGCCCTCCTGGR~T~~~~GGflGflG~~GGGTTTCCCCGGflTTCCCTGG~CTGG~C 
761 GPPGGQGPPGLSGPPGIKGEKGFPGFPGLD 
2377 RTGCCGGGCCCTRARGGRGRTRRAGGGGCTCRREGRCTCCCTGGC~T~~CGGG~CflGTCGGGGCTCCCTGGCCTTCCTGG~CflGC~GGGG 
811 aPIG P KGDKGROGLPGITGOSGLPGLPGOOG 
2467 GCTCCTGGGRTTCCTGGGTTTCCRGGTTCCRRtttAORAATGGGT 
641 RPGlPGFPGSKGEllGUflGTPGOPGSPGPUG 
2557 GCTCCTGGRTTRCCGGGTGRARRAOOOOReCRTGGCTTTC~GGTG~Tn~GGGG 
671 RPGLPGEKGD"GFPGSSGP~~~,~~~PGLKGDKG 
,...,.. 
2647 GRTGTCGGTCTCCCTGGCRRGCCTGGCTCCRT GAlRAGGTGGRCRTGGGCRGCATtRROGGCCRtRRROGAO~CC~~GGRG~G~R~GG~ 
901 DUGLPGKPGSilOKUDflGSflKGOKGOQGEKG 
2737 CARATTGGRCCARTTGGTGAGARG6tRTC~,~~~~~~,~~CCCTGGG~CCCCflGGRGTGCCTGGfl~~GG~CGGGCflGGCRGGflCRGCCTGGG 
931 0 I GPIGEKGS~~~~~PGTPGUPGKOGQRGOPG 
2627 CRGCCRGGRCCTRRAGGTGRTCCROOTRTAAOTGGRRCCCC~GGTGCTCC~GG~CTTCCGGG~CC~~flflGGnTCTGTTGGTGG~~TGGGC 
961 0 P G P KG D P G IS G T P G A P G L P G P KG S U G G 0 G 
2917 TTGCCRGGARCRCCTGGAGAtARAOGTGTGCCTGGCRTCCCCRC~~GGTTCRCCTGGCTTnCCTGG~GRC~~RGGTGCRnn~GGfl 
991 LPGTPGEKGUPGIPGPOGSPGLPGOKG!4KG 
3007 GRGAARGGGCRGGCRGGCCCACCT 
?i 
RGGCATCCCAGGGCTGCGRGOTORRARGOOROATCRAGGG~G~TC~~GGG~TflGCGGGTTTCCC~GG~nGC 
1021 EKGQAGPPGlGlPGLRGEKGOQGlflGFPGS 
3097 CCTGGRGRGRRGGGAGRRARAttAROEATTGGGflTCCCATCCCC~GGCCTTfl~RGGGTCTCCCGGG~GTGTTGGCTflT 
1051 PGEKGEKGSIGIPGllPGSPGLKGSPGSUG'f 
3167 CCAGGAAGTCCTGGGCTRCCTGGRG~~flR~GGTG~C~~RGGCCTCCC~GGRTTGG~TGGC~TCCCTGGTGlC~flflGGRG~~GC~GGTCTT 
1061 PGSPGLPGEKGOKGLPGLDGIPGUKGERGL 
3277 CCTGGGACTCCTGGCCCCRCflGGCCCAOCTGOCCRtARAOnGfl~GGGTGnn 
1111 PGTPGPTGPRGOKGEPGSDGIPGSRGEKGE 
3367 CCRGGTCTRCCA A RGGnTTCCCRGGGTTTCCRGGGGCCAAROtrRtACRRAOOTTC~~nGGGTG~GGTGGGTTTCCC~GG~TT~GCC 
I141 PGLPGRGFPGFPGAKGDKGSKGEUGFPGLR fY 
3457 GGGRGCCCRGGRATTCCTGGnTCCn~~GG~G~GCnnGGnTTCnTGGGTCCTCCGGGGCCCC~GGG~CnGCCGGGGTTnCCGGGflTCCCC~ 
1171 GSPGIPGSKGEQGFflGPPGPOGQPGLPGSP 
3547 GGCCRTGC 
1201 GHRTEGPKGDRGPOGfJPGLPGLPGPflGPPG m 
GGGGCCCRflRGGRGACCGCGGRCCTCAttOCCRGCCTOOCCTGCC~GG~CTTCCGGG~CCC~TGGGGCCTCC~GGG 
1231 LPGIGGUKGOKGNPGUPGAPGUPGPKGOPt 
1261 FQGflPGlGGSPGITGSKGDflGPPGUPGFOG 
1291 PKGLPGLQGIKGDQGDQGUPG~KGLPGPPG 
1321 PPGPY~GEPGLPGPEGPPGLKGLOGLP 
1351 GPKGOQGUTGLUGIPGPPGIPGFDG!3PGQK 
1361 GEflGPAGPTGPRGFPGPPGPDGLPGSflGPP 
1411 GTPSUDHGFLUTRHSQTlDDPQ@PSGTKlL I 
1141 YHGYSLLYUQGNERAUGODLGTflGS@LRKF 
1471 STIlPFLF@NlNNU@NFASRNDvsvuLsrpE 
1501 PllPflSflAPITGENlRPFISR@RU@EtlP~~U 
1531 llAUHSQTlQlPP@PSGUSSLUlG~SFUflHT 
1561 SRGAEGSGQRLASPGS@LEEFRSRPFlE@H 
1591 GRGT@NYYRNRYSFULRTlERSEnFKKPTP 
1621 STL KRG ELRTHUSR@QU@flRRT 
2266 
760 
2376 
610 
2466 
640 
2556 
670 
2646 
900 
2736 
930 
2026 
960 
2916 
990 
3006 
1020 
3096 
1050 
3166 
IOLIO 
3276 
1110 
3366 
1140 
3456 
1170 
3546 
1200 
3636 
1230 
1260 
1290 
1320 
1350 
1380 
1410 
1440 
1470 
1500 
1530 
1560 
1590 
1620 
1642 
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TRIPLE HELIX 
I 
NC-DOMAIN 
0 Gly-X-Y-repeats 
Noncollagenous sequence 
AMINO ACID RESIDUES 
Fig.3. Primary structure of the al-chain of human type IV collagen. Interruptions of the collagenous (Gly-X-Y) 
sequence are marked by shaded boxes. Cysteine residues are indicated by C. 
terruption number 9 (table 1). One or more of the IV coliagenase [31]. The sequence of the cleavage 
last three cysteine residues must participate in in- site has not been determined but it has been 
terchain disulfide bonds because the carboxy- measured from degradation fragments visualized 
terminal fragment generated by type IV col- by rotary shadowing to be 89 + 10 nm from the 
lagenase, containing about 75% of the length of amino-terminal end of the polypeptide chain [30]. 
the chain, is disulfide bonded [30]. This knowledge makes it possible to prepare syn- 
The present data provide the sequence of the thetic peptides that might serve as enzyme in- 
region of the ai(chain that is cleaved by type hibitors or substrates for the enzyme. 
Table 1 ACKNOWLEDGEMENTS 
Interruptions in the triple-helical (Gly-X-Y), sequence of 
the human aI(chain 
Helix Amino acid Amino acid 
interruption residue number sequence 
1 136- 145 LGHVPGMLLK 
2 197- 198 3 220 230 QVQE:zDFATK 
4 246- 247 GV 
5 308- 310 IGT 
6 350- 351 VP 
7 376- 371 LP 
8 402- 409 NGIVECQP 
9 440- 446 CLICDID 
10 507- 513 YFDLRLK 
11 580- 581 GY 
12 615- 618 VPLP 
13 661- 662 GI 
14 708- 709 GV 
15 773- 714 GI 
16 811- 812 MP 
17 912- 916 DKVDM 
18 1029-1030 GI 
19 1145-1146 GR 
20 1204-1205 HATE 
21 1326-1329 DIIK 
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